Assessment of the Endotest® saliva test in complex endometriosis diagnosis situations

Aim

• To assess the self-referral by the HAS in July 2023 relating to the clinical utility of the Endotest® saliva test for complex endometriosis diagnosis situations.
• The objective is to inform the HAS Board’s decision with a view to determining whether reimbursement of the test by the French national health insurance system is valid in a relevant indication.
• At the time of the assessment, this 109-miRNA saliva signature test using a sophisticated next-generation sequencing method is in the validation phase and is the only test currently with CE marking in endometriosis.